Teva Announces Tentative Approval Of Generic Diovan(R) Tablets
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted tentative approval for the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of Novartis’ hypertension treatment Diovan® (Valsartan) Tablets, 40 mg, 80 mg, 160 mg and 320 mg.
More: continued here
Filed under: Hypertension on June 19th, 2008